丁丙诺啡联合氯诺昔康用于肝癌术后患者静脉自控镇痛的临床观察  

Clinical Observation of Patients Controlled Intravenous Analgesia with Buprenorphine and Lornoxicam After Operations of Hepatic Cancer

作　　者：周泉华[1] 梅菊香[1] 

机构地区：[1]启东肝癌防治研究所,江苏启东226200

出　　处：《肿瘤基础与临床》2010年第6期518-520,共3页journal of basic and clinical oncology

摘　　要：目的观察丁丙诺啡联合氯诺昔康用于肝癌术后静脉自控镇痛(PCIA)的疗效及毒副反应。方法择期手术肝癌80例随机分为丁丙诺啡+氯诺昔康组(A组)和芬太尼+氯诺昔康组(B组),每组40例,分别在术后用丁丙诺啡0.25μg/(kg.h)+氯诺昔康10μg/(kg.h)和芬太尼0.25μg/(kg.h)+氯诺昔康10μg/(kg.h)行PCIA,背景剂量2 mL/h,单次按压剂量0.5 mL/次,锁定时间15 min,记录按压次数及术后4、8、12、24、48 h的VAS疼痛评分和Ramsay镇静评分,并观察毒副反应及循环、呼吸的变化。结果 A、B组各时点按压次数、VAS评分和Ramsay镇静评分差异无统计学意义(P>0.05);A组恶心呕吐发生率较B组低(P<0.05);两组嗜睡、头晕、呼吸抑制发生率差异无统计学意义(P>0.05)。结论丁丙诺啡联合氯诺昔康可安全用于PCIA,镇痛效果确切,毒副反应轻。Objective To observe the effects and toxicities of patients controlled intravenous analgesia（PCIA） with buprenorphine and lornoxicam after operations of hepatic cancer.Methods Eighty patients with hepatic cancer were divided into two groups randomly,each of 40 cases.PCIA was carried out with buprenorphine 0.25 μg/（kg·h） and lornoxicam 10 μg/（kg·h） in the buprenorphine＋lornoxicam group（group A）,and fentanyl 0.25 μg/（kg·h） and lornoxicam 10 μg/（kg·h） in the fentanyl＋lornoxicam group（group B）.PCIA was set at constent pumping dose of 2 mL/h,with a bolus dose of 0.5 mL and locked time 15 min.VAS score and Ramsay score were recorded at 4,8,12,24 and 48 h after operation.The number compressed by patient,toxicities during analgesia,and circular and respiratory changes were recorded as well.Results There were no significant differences in compress number,VAS score and Ramsay score between the two groups.The incidence of nausea and vomiting in the group A was lower than that in the group B.There were no significant differences in the incidences of lethargy,dizziness and respiratory depression between the two groups.Conclusion PCIA with buprenorphine and lornoxicam is effective and safe.

关 键 词：丁丙诺啡 氯诺昔康 芬太尼 肝癌 静脉自控镇痛 

分 类 号：R730.6[医药卫生—肿瘤]